Global Home Global Home  
 
 

News

Date Title and Summary Additional Formats
Toggle Summary Oculus Innovative Sciences Receives FDA Clearance for Microcyn®-Based SebDerm Gel
U.S. Launch During June Quarter 2016
View HTML
Toggle Summary Oculus Innovative Sciences Reports Financial Results for the Second Quarter of Fiscal Year 2016
Total Revenue of $4.1 Million Increased 24%—Led by 64% Increase in Product Revenue—Driven by Growth in U.S. Dermatology Sales Conference Call at 4:30 pm ET Today PETALUMA, Calif. , Nov. 05, 2015 (GLOBE NEWSWIRE) -- Oculus Innovative Sciences, Inc. (NASDAQ:OCLS), warrants (Nasdaq:OCLSW), a specialty
View HTML
Toggle Summary Oculus Innovative Sciences Announces Fiscal Second Quarter 2016 Financial Results and Conference Call
PETALUMA, Calif. , Oct. 22, 2015 (GLOBE NEWSWIRE) -- Oculus Innovative Sciences, Inc. (NASDAQ:OCLS), tradable warrants (NASDAQ:OCLSW) today announced that the financial results for its fiscal second quarter 2016, ended September 30, 2015 , will be released after the U.S.
View HTML
Toggle Summary Oculus Innovative Sciences Introduces MicrocynAH(R) Next-Generation Dermatology Products With Dimethicone for Animals
PETALUMA, Calif. , Sept. 24, 2015 (GLOBE NEWSWIRE) -- Oculus Innovative Sciences, Inc. (NASDAQ:OCLS) (tradable warrants OCLSW), a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care in both humans and animals,
View HTML
Toggle Summary Oculus Innovative Sciences Announces Preliminary Results for Its 2015 Annual Meeting of Stockholders
PETALUMA, Calif. , Sept. 11, 2015 (GLOBE NEWSWIRE) -- Oculus Innovative Sciences, Inc. (NASDAQ:OCLS), tradeable warrants (NASDAQ:OCLSW) today announced that the four proposals presented in its annual meeting proxy statement have, through September 10, 2015 , received the affirmative vote of more
View HTML
Toggle Summary Oculus Innovative Sciences Announces Introduction of Alevicyn SG Antipruritic Spray Gel for Relief of Pain and Itch in Atopic Dermatitis
PETALUMA, Calif. , Aug. 19, 2015 (GLOBE NEWSWIRE) -- Oculus Innovative Sciences, Inc. (NASDAQ:OCLS), a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care, today announced the launch of the company's new
View HTML
Toggle Summary Oculus Innovative Sciences Reports Financial Results for the First Quarter of Fiscal Year 2016
U.S. dermatology and Latin American sales drive 37% product revenue growth FDA 510k clearance for treatment of atopic dermatitis with a unique "no touch" spray gel Cash as of June 30, 2015 of $8.8 million and debt free Conference call begins at 4:30 p.m. EDT today PETALUMA, Calif.
View HTML
Toggle Summary Oculus Innovative Sciences Announces Fiscal First Quarter 2016 Financial Results and Conference Call
PETALUMA, Calif. , July 16, 2015 (GLOBE NEWSWIRE) -- Oculus Innovative Sciences, Inc. (Nasdaq:OCLS), today announced that the financial results for its fiscal first quarter 2016, ended June 30, 2015 , will be released after the U.S. markets close on July 30, 2015 .
View HTML
Toggle Summary Oculus Innovative Sciences Receives New U.S. Patent for Microcyn(R) Technology in Treatment of Atopic Dermatitis
PETALUMA, Calif. , July 8, 2015 (GLOBE NEWSWIRE) -- Oculus Innovative Sciences, Inc. (Nasdaq:OCLS), a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care, today announced the receipt of a new U.S.
View HTML
Toggle Summary Oculus Innovative Sciences Regains Compliance With NASDAQ Minimum Bid Price Rule
PETALUMA, Calif. , June 18, 2015 (GLOBE NEWSWIRE) -- Oculus Innovative Sciences, Inc. (Nasdaq:OCLS) (Nasdaq:OCLSW), a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care, today announced that it received a
View HTML